Introduction
Fibrotic tissue remodeling imposes a major burden on modern societies and has been estimated to contribute to up to 45% of deaths in the developed world and to cause socioeconomic costs in the order of tens of billions of dollars per year (1, 2) . Fibrotic tissue remodeling may occur in response to trauma, infection/inflammation or tumors, but in many cases, no initiating triggers can be identified. Systemic sclerosis (SSc) is a prototypical example of such an idiopathic fibrotic disease (3) . Failure of the affected organs is common in SSc and results in high morbidity and mortality, particularly because no targeted therapies are yet available for the treatment of fibrosis (3, 4) . Aberrant activation of resident fibroblasts and their transition into myofibroblasts is the common denominator of fibrotic diseases (2) (3) (4) . Overwhelming evidence highlights transforming growth factor-β (TGFβ) as a core mediator of fibroblast activation (3) (4) (5) (6) (7) . TGFβ signaling is chronically activated in SSc and other fibrotic diseases and activated fibroblasts demonstrate a TGFβ biased gene expression signature, which persists in vitro (8) (9) (10) (11) . Moreover, TGFβ is sufficient to induce myofibroblast differentiation in vitro and tissue fibrosis in vivo (12) .
While myofibroblasts are only transiently observed during physiological wound healing, they persist in fibrotic diseases, resulting in persistent repair responses and progressive tissue fibrosis. More than 40 years ago, LeRoy and colleagues provided first evidence for an endogenous activation of SSc fibroblasts demonstrating that SSc fibroblasts maintain an activated phenotype in vitro, even in the absence of other cell types or constituents of the profibrotic milieu in SSc (13) . Endogenous activation of TGFβ in SSc fibroblasts in cell culture is critical to maintain this persistently activated phenotype (14) . This finding suggested that, although myofibroblast differentiation may initially be driven by external factors, prolonged activation could render them autonomous and independent of external stimuli.
Changes in the epigenetic code are central for establishing and maintaining the activated phenotype of fibroblasts in fibrotic diseases (15) (16) (17) (18) (19) (20) . Amongst the different epigenetic modifications, DNA methylation remains most intensely studied. Methylation of DNA occurs on position 5 of the pyrimidine ring of cytosine residues within CpG dinucleotides and leads to transcriptional silencing (21) . A family of DNA methyltransferases (DNMT) comprising three members in mammals controls DNA methylation: DNMT1, which is predominantly a maintenance methyltransferase with a preference for hemimethylated sites, and DNMT3A and DNMT3B, which are thought to function mainly as de novo DNA methyltransferases (21) (22) (23) .
DNA methylation may drive fibrosis by silencing of anti-fibrotic genes (24) (25) (26) (27) (28) , as evidenced by downregulation of the antifibrotic transcription factors FLI1 and KLF5 in SSc (29, 30) .
Those findings are of therapeutic interest, as epigenetic changes are reversible. DNMTs can be targeted by small molecule inhibitors like 5-azacitidine and 5-aza-2'-deoxycytidine, which are already approved for clinical use in myelodysplastic syndrome and acute myeloid leukemia.
Janus kinases (JAKs) / signal transducer and activator of transcription (STAT) signaling pathways are well established as crucial mediators of inflammation (31, 32) . Small molecule inhibitors of JAKs are approved for clinical use in rheumatoid arthritis and await approval for other inflammatory diseases. In fibrotic diseases, however, the role of JAK / STAT signaling is not restricted to the regulation of inflammation. We and others have demonstrated recently that JAK2 / STAT3 signaling also transmits the profibrotic effects of TGFβ on fibroblasts and that targeted inhibition of JAK2 or STAT3 ameliorates fibroblast activation and fibrosis (33) (34) (35) . JAK2 / STAT3 may thus not only modulate fibrotic tissue remodeling by regulating inflammatory responses, but also by directly controlling fibroblast activation. Two members of the suppressor of cytokine signaling (SOCS) proteins, SOCS1 and SOCS3, are crucial regulators of JAK / STAT signaling. The family of SOCS proteins consists of eight members, SOCS1 to SOCS7 and CIS (cytokine-induced SH2 containing protein), which share a central SH2 domain and a SOCS box at the C-terminus. However, only SOCS1 and SOCS3 possess an N-terminal kinase inhibitory region (KIR) domain, which enables them to block the transfer of competitive inhibitors of JAKs. In addition, SOCS proteins may also induce degradation of JAKs and of the associated cytokine receptors (39) . Of note, SOCS proteins are transcriptional targets of STAT proteins: activation of STAT signaling induces the expression of SOCS proteins to provide a negative feedback loop (39) . This endogenous feedback regulation is critical to prevent aberrant activation of JAK / STAT signaling. Loss-of-function mutations of SOCS proteins with consecutive activation of JAK / STAT signaling have been observed in different hematologic and solid tumors (40) (41) (42) (43) . However, more commonly than by somatic mutations, tumor cells escape the endogenous regulation of JAK / STAT signaling by epigenetic imprinting of SOCS genes (44) . Hence, in various types of B cell neoplasias and carcinomas, the expression of SOCS1 or SOCS3 is silenced by DNA hypermethylation (43, (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) .
In the present study, we tested the hypothesis that epigenetic silencing of SOCS expression may contribute to the aberrant activation of JAK2 / STAT3 signaling by TGFβ in SSc, and that reestablishment of the endogenous, SOCS-dependent control of JAK / STAT signaling may prevent aberrant fibroblast activation and ameliorate tissue fibrosis.
Results

The expression of SOCS3 is downregulated in SSc and in experimental skin fibrosis in a
TGFβ-dependent manner
We first analyzed the expression of SOCS proteins in fibrotic skin of SSc patients. The mRNA and protein levels of SOCS3 were decreased in SSc skin as compared to healthy individuals of the same age and sex ( Figure 1A ). We also found reduced staining for SOCS3 in fibroblasts in SSc skin by co-staining for SOCS3 and the fibroblast marker prolyl-4-hydroxylase-β (P4Hβ) ( Figure 1B ). The downregulation of SOCS3 persisted in cultured SSc fibroblasts with decreased mRNA and protein levels of SOCS3 as compared to fibroblasts from normal skin ( Figure 1C ).
The reduction of SOCS3 protein levels and of the number of SOCS3-positive fibroblasts was more pronounced in diffuse-cutaneous SSc than in limited cutaneous SSc (Supplementary Figure 1 ). The expression of SOCS3 was also reduced in experimental fibrosis with decreased staining in vimentin-positive cells in the skin of mice challenged with bleomycin as compared to non-fibrotic controls ( Figure 1D ). In contrast to SOCS3, we did not observe changes in SOCS1 expression in SSc or in experimental dermal fibrosis (data not shown), indicating a SOCS3-specific deregulation.
Given the consistent downregulation of SOCS3 expression in human SSc skin, in cultured SSc fibroblasts and in experimental fibrosis, we hypothesized that a core pathway of fibrosis, such as TGFβ, may regulate SOCS3 expression. Stimulation of cultured fibroblasts with recombinant TGFβ induced an early, transient upregulation of SOCS3 ( Figure 1E ). However, with prolonged follow-up, the mRNA and protein levels of SOCS3 declined strongly to below baseline levels.
The downregulation of SOCS3 was maintained and SOCS3 expression remained stably suppressed when fibroblasts were exposed to persistently increased levels of TGFβ as in fibrotic tissues ( Figure 1E ). Vice versa, incubation of SSc fibroblasts with SD-208, a selective inhibitor of TGFβ receptor I kinase activity, increased SOCS3 expression to levels that were comparable to that of normal fibroblasts ( Supplementary Figure 2A) . The regulatory effects of TGFβ on SOCS3 were confirmed in vivo. Activation of TGFβ signaling by overexpression of a constitutively active TGFβ receptor type I (TBRI act ) decreased the expression of Socs3 in murine skin ( Figure 1F , G). Moreover, the downregulation of Socs3 in bleomycin-and TBRI actinduced fibrosis was blocked by selective inhibition of TGFβ signaling with SD-208 ( Figure   1F , G), confirming that TGFβ is both sufficient and required to downregulate SOCS3 expression in skin fibrosis.
TGFβ inhibits SOCS3 expression by hypermethylation of the SOCS3 promoter
The findings of a persistent downregulation of SOCS3 expression in cultured SSc fibroblasts and the repression of SOCS3 upon stimulation with TGFβ suggested that epigenetic mechanisms might account for the reduced expression of SOCS3. In cancer cells, the transcription of SOCS3 has been shown to be regulated by DNA methylation (54, 59) . To evaluate whether DNA methylation is implicated in the downregulation of SOCS3 expression in SSc, we first inhibited the activity of DNA methyltransferases (DNMT) by 5-aza-2'deoxycytidine (5-aza) . In SSc fibroblasts, incubation with 5-aza increased the mRNA and protein levels of SOCS3 in a time-dependent manner ( Figure 2A ). In contrast, 5-aza had no significant effects on the steady-state expression of SOCS3 in fibroblasts derived from healthy individuals ("normal" fibroblasts) ( Figure 2B ). To directly demonstrate hypermethylation of the promoter region of the SOCS3 gene in SSc fibroblasts, we performed methylation-specific PCR. The ratio of methylated to unmethylated DNA was higher in fibroblasts from SSc skin compared to fibroblasts isolated from the skin of healthy individuals ( Figure 2C ). Methylated DNA immunoprecipitation (MeDIP) analysis of 14 sites throughout the CpG island in the promoter of the SOCS3 gene demonstrate that hypermethylation occurs in particular at -1402 to -1313, -981 to -545, -784 to -654, -661 to -545, -353 to -223 and +75 to +217 with 40-to 100-fold increases in SSc fibroblasts as compared to fibroblasts from healthy individuals. These sites were consistently hypermethylated in all lines of fibroblasts derived from patients with diffuse-cutaneous SSc ( Figure 2C and Supplementary Figure 3 ). We also detected low levels of methylation at sites -1202 to -1053, -419 to -311 and -127 to +21 with trends towards slight increases in SSc fibroblasts ( Figure 2C and Supplementary Figure 3 ). Consistent with the lack of differences in expression of SOCS1, we did not observe differences in the methylation status of the promoter of SOCS1 in SSc fibroblasts (data not shown).
We next investigated whether epigenetic imprinting by promoter hypermethylation also accounts for the repression of SOCS3 expression upon prolonged stimulation with TGFβ.
Indeed, incubation with 5-aza prevented the downregulation of SOCS3 mRNA and protein in dermal fibroblasts from healthy donors upon prolonged exposure to TGFβ ( Figure 2D ). However, 5-aza did not further increase the levels of SOCS3 in SSc fibroblasts pre-incubated for extended periods with SD-208 ( Supplementary Figure 2A) , highlighting that the endogenous downregulation of SOCS3 in SSc is dependent on the well-known hyperactive TGFβ signaling in these cells (14) . Moreover, repression of SOCS3 in the skin of TBRI act mice was reversed by the co-treatment with 5-aza ( Figure 2E ). Similar results were obtained in bleomycin-induced skin fibrosis ( Figure 2F ). Consistent with the findings obtained with 5-aza, methylation-specific PCR and MeDIP assays demonstrated an upregulation of DNA methylation at the SOCS3 promoter at -784 to -654, the most highly methylated site in SSc fibroblasts, by TGFβ in normal fibroblasts, which was prevented by co-incubation with 5-aza ( Figure 2G ).
To test whether TGFβ promotes DNA methylation by regulation of DNMT expression, we monitored the expression levels of all three DNMTs in fibroblasts stimulated with TGFβ over time. TGFβ upregulated the expression of DNMT1 and DNMT3A, but had no effect on the mRNA and protein levels of DNMT3B ( Figure 3A) . Notably, the kinetics of the induction of DNMT1 and DNMT3A differed. First effects of TGFβ on DNMT3A expression occurred within 6 h with significant effects after 12 h, while an induction of DNMT1 did not occur before 72 h ( Figure 3A ). The differences in the kinetics suggest an indirect induction of DNMT1, whereas DNMT3A may be regulated directly by TGFβ. Indeed, the upregulation of DNMT3A mRNA by TGFβ did not require de novo protein synthesis as analyzed by co-incubation with cycloheximide (data not shown). Stimulation with TGFβ also induced DNMT activity in fibroblasts with first effects within 4 h ( Figure 3B ).
SiRNA-mediated knockdown of SMAD3 and SMAD4 demonstrated that TGFβ induces DNMT3A by canonical TGFβ signaling (Supplementary Figure 2B , C). In contrast, targeted inhibition of non-canonical TGFβ downstream mediators such as JNK, p38, Ras or Rac had no effect (data not shown). To further confirm the direct regulation of DNMT3A expression by TGFβ-induced SMAD3 signaling, we analyzed the DNMT3A promoter for potential SMAD3 binding sites and performed ChIP assay. In silico analyses of the DNMT3A promoter revealed four SMAD binding elements (SBE). ChIP assays demonstrated that TGFβ induced SMAD3 binding to the DNMT3A promoter at -3423 bp (Supplementary Figure 2D ). Thus, TGFβ regulates DNA methylation in fibroblasts by SMAD3-dependent upregulation of DNMT3A expression.
The different kinetics of DNMT1 and DNMT3A induction by TGFβ may also reflect the functional differences of both DNMTs with DNMT3 acting predominantly as a de novo DNA methyltransferase and DNMT1 rather maintaining established DNA methylation (21) .
Consistent with this interpretation, individual knockdown of DNMT3A, but also of DNMT1, was each sufficient to completely prevent the downregulation of SOCS3 upon prolonged incubation with TGFβ in normal fibroblasts and to reactivate the baseline expression of SOCS3 in SSc fibroblasts ( Figure 3C Figure 2E ). Together, these data demonstrate that TGFβ induces DNMT3A and DNMT1 in a SMAD-dependent manner to silence the expression of SOCS3 by promoter hypermethylation in SSc.
SOCS3 limits TGFβ-dependent fibroblast activation
To investigate the functional role of SOCS3 in fibroblast activation in SSc, we first targeted the expression of SOCS3 in fibroblasts. SiRNA-mediated knockdown of SOCS3 in dermal fibroblasts from healthy volunteers increased mRNA levels of COL1A1 and COL1A2, stimulated the release of collagen protein and promoted the expression of αSMA and the formation of stress fibers to levels almost comparable to that of SSc fibroblasts ( Figure 4A and Supplementary Figure 4B ). In contrast to the effects on normal fibroblasts, knockdown of SOCS3 had no further effects on collagen release or the expression of myofibroblast markers in SSc fibroblasts, a finding that is in line with the promoter methylation-induced silencing of SOCS3 in SSc fibroblasts ( Figure 4C and Supplementary Figure 4D ).
Co-incubation with 5-aza to prevent the downregulation of SOCS3 reduced the stimulatory effects of TGFβ on normal fibroblasts and reduced the upregulation of COL1A1 and COL1A2 mRNA, of collagen protein, of αSMA and of stress fibers ( Figure 4A and Supplementary Figure   4B ), but had no significant effects on the basal expression levels in normal fibroblasts.
Moreover, incubation with 5-aza also reversed the activated phenotype of established myofibroblasts, when applied 72 h after first exposure to TGFβ (Supplementary Figure 5) . To exclude that the increased sensitivity of SSc fibroblasts to the antifibrotic effects of 5-aza is based on enhanced proliferation of these cells, all experiments were performed with confluent and thus contact-inhibited, non-proliferating cells. Moreover, co-incubation with cell cycle inhibitors did not ameliorate the differences in responsiveness to 5-aza between SSc fibroblasts and normal fibroblasts (data not shown).
By contrast, forced overexpression of SOCS3 inhibited TGFβ-induced fibroblast activation in normal fibroblasts with reduced induction of COL1A1 and COL1A2 mRNA as well as the release of collagen ( Figure 5A 
Inhibition of epigenetic silencing of Socs3 ameliorates experimental fibrosis
To investigate the role of Socs3 in the pathogenesis of experimental fibrosis, we evaluated the outcome of mice with fibroblast-specific deletion of Socs3 (Socs3 fl/fl ;Col6Cre) in bleomycinand TBRI act -induced skin fibrosis. Socs3 fl/fl -and Col6Cre mice presented with normal skin architecture and comparable responses to profibrotic stimuli as wildtype mice (data not shown). SOCS3 inhibits JAK2 / STAT3 signaling to regulate TGFβ-dependent fibroblast activation SOCS3 can bind to JAK1, JAK2 and TYK2 to inhibit their kinase activity preventing subsequent activation of STAT and transcription of STAT-dependent target genes (37, 38) . We and others previously demonstrated that stimulation with TGFβ activates JAK2 / STAT3 signaling in fibroblasts, characterized JAK2 and STAT3 as important intracellular mediators of TGFβ signaling and demonstrated enhanced activation of JAK2 / STAT3 signaling with accumulation of phosphorylated JAK2 (pJAK2) and phosphorylated STAT3 (pSTAT3) in SSc (33) (34) (35) 60) . We thus tested the hypothesis that SOCS3 may regulate fibroblast activation by inhibiting TGFβ-induced JAK2 / STAT3 signaling. Indeed, when we knocked down JAK2 in addition to SOCS3 in normal fibroblasts, we were able to completely rescue the activated phenotype of SOCS3 knockdown fibroblasts ( Supplementary Figure 9 ). The mRNA levels of COL1A1 and of COL1A2 and the release of collagen protein were reduced in fibroblasts with combined knockdown of JAK2 and SOCS3 compared to fibroblasts with individual knockdown of SOCS3 and were similar to those of fibroblasts with individual knockdown of JAK2 (Supplementary Figure 9A ). In addition, co-knockdown of JAK2 in addition to SOCS3 reduced the activation of fibroblasts with decreases in αSMA expression and stress fiber formation Figure 9C) . Co-immunoprecipitation further demonstrated that co-incubation of TGFβ-stimulated fibroblasts with 5-aza restored the negative feedback regulation by SOCS3 with increased binding of SOCS3 to JAK2 and decreased interaction of JAK2 with STAT3 ( Figure 8A ). Consistently, co-incubation with 5-aza inhibited the stimulatory effects of TGFβ on STAT3-regulated transcription in reporter assays ( Figure 8B ). The inhibitory effects of 5aza on STAT3-dependent transcription were absent in SOCS3 knockdown fibroblasts. In contrast, knockdown of DNMT3A significantly decreased the responsiveness to TGFβ and reduced the STAT3 reporter activity ( Figure 8B ). Forced overexpression of SOCS3 inhibited STAT3-dependent transcriptional activity in these assays and the effect of forced overexpression of SOCS3 was not sensitive to 5-aza (data not shown).
To further demonstrate that the activated phenotype of SOCS3 knockdown fibroblasts is caused by hyperactivation of JAK2 / STAT3 signaling, we overexpressed a mutant version of JAK2 with point mutations in the GQM binding motif that is required for binding of SOCS3 (JAK2-G1071V;M1073A) (36) . Incubation with 5-aza upon forced overexpression of wildtype JAK2 Supplementary Figures 11 -14) . However, such inhibitory effects of 5-aza on Jak2 / Stat3 activation were not observed in fibroblast-specific Socs3 mutants (Socs3 fl/fl ;Col6Cre mice), indicating that Socs3 is essentially regulating Jak2 / Stat3 signaling. ( Supplementary Figure 11 and 12). Conversely, when investigating fibroblast-specific Dnmt3a mutants (Dnmt3a fl/fl ;Col6Cre mice), which are associated with high-level Socs3 expression, bleomycin 5-aza had no further effects on Jak2 and Stat3 activation.
In the present study, we demonstrate that the expression of SOCS3 is reduced in fibroblasts of the fibrotic skin of SSc patients, a phenotype that persists even in isolated fibroblasts after longterm in vitro culture. The expression of Socs3 is also decreased in murine models of skin fibrosis. We show on multiple experimental levels that canonical TGFβ signaling plays an Mechanistically, TGFβ reduces the expression of SOCS3 by induction of DNMT3A, which silences SOCS3 expression by DNA methylation. We demonstrate by methylation-specific PCR and MeDIP assays that the promoter of SOCS3 is hypermethylated in SSc fibroblasts as compared to fibroblasts from healthy individuals. Stimulation of normal fibroblasts with recombinant TGFβ not only leads to transformation into an SSc-like fibroblast phenotype, but also upregulates methylation of the SOCS3 promoter to levels comparable to those observed in SSc fibroblasts. The downregulation of SOCS3 in SSc fibroblasts is thus consistent with the persistent activation of TGFβ signaling in these cells even after several passages in vitro (4) .
The stimulatory effects of TGFβ on SOCS3 promoter methylation are mediated by a SMADdependent induction of DNMT3A. Prolonged incubation with TGFβ also induced the expression of DNMT1. However, the kinetic profiles of DNMT3A and DNMT1 upregulation suggest that DNMT3A is induced directly and operates as de novo DNA methyltransferase at the SOCS3 promoter, whereas DNMT1 is induced indirectly and rather serves to maintain the pre-existing DNA methylation marks (21) . According to this model, the activity of both DNMTs would be required to chronically sustain promoter hypermethylation of SOCS3 and inactivation of either DNMT1 or DNMT3A would prevent chronic silencing of SOCS3 and other target genes (24, 63) . Consistently, we found that, in addition to the pronounced upregulation of DNMT3A, the expression of DNMT1 was also increased in SSc.
Previous elegant studies demonstrated that the protective anti-fibrotic transcription factors FLI1 and KLF5 are silenced by DNA hypermethylation in SSc and that their silencing is directly implicated into different aspects of the pathogenesis of SSc (29, 30, 64) . Our study demonstrates highlighting that STAT3 is considered as a prime target for pharmaceutical intervention and that numerous compounds would be available for clinical trials in SSc.
Our data also strengthen the scientific rational for targeting DNA methylation in fibrotic diseases. Deletion of Dnmt3a or Dnmt1 or pharmacologic inhibition of Dnmts ameliorated fibrosis induced by bleomycin or by TBRI act . Of note, treatment with 5-aza was not only effective in preventive, but also in therapeutic settings and did not only inhibit further progression, but also induced regression of pre-established fibrosis. Inhibition of DNMTs would not only limit aberrant STAT3 signaling in SSc, but would also exert anti-fibrotic effects by reactivation of protective genes such as FLI1 and KLF5 (29, 30) .
However, the simultaneous modulation of several pathways by epigenetic modifiers may not only add to the therapeutic effects, but may also carry a higher risk of adverse events as it may also interfere with pathways that are not relevant to the pathogenesis of SSc. However, these concerns may be limited by recent findings that treatment with 5-aza does not cause random DNA demethylation (65) . Instead, treatment with 5-aza predominantly modulates the expression of a panel of regulatory genes, while it had little effects on the methylation status of homeostatic genes. In addition to potential effects on fibrotic manifestations, accumulating evidence also suggests that aberrant DNA methylation may also be implicated in vascular and inflammatory manifestations of SSc and other rheumatic diseases (20, 66, 67) . Inhibition of DNA methylation may thus offer unique potential to improve a broad spectrum of manifestations of SSc. However, further studies in additional preclinical models that better resemble vascular and inflammatory manifestations of SSc are warranted to confirm this hypothesis.
In summary, we demonstrate that chronic activation of TGFβ signaling perturbs the epigenetic control of STAT signaling by DNMT3A-induced silencing of SOCS3 expression ( Figure 9 ).
Re-establishment of the endogenous regulation of STAT signaling, either by forced expression of SOCS3 or by inhibition of DNMTs, prevents aberrant STAT3 signaling, inhibits TGFβinduced fibroblast activation and collagen release and ameliorates experimental fibrosis.
Restoration of the epigenetic control of STAT3 signaling might thus be a novel approach for the treatment of fibrotic diseases such as SSc.
Patients and fibroblast cultures
Skin biopsies were obtained from the forearm of 38 SSc patients and 42 age-and sex-matched healthy volunteers. All patients fulfilled the ACR/EULAR criteria for SSc (68) . Twenty-two patients had diffuse cutaneous SSc, sixteen limited cutaneous SSc. The median age of SSc patients was 46 years (range: 19 -70 years) and their median disease duration was 5 years (range: 0.5 -12 years). All patients were positive for antinuclear antibodies; fourteen patients were positive for anti-topoisomerase-1 antibodies, twelve were positive for anti-centromere antibodies, two for anti-RNAIII polymerase antibodies. Patients did not receive any diseasemodifying anti-rheumatic drug treatment at the time of biopsy.
Cell culture
Fibroblasts were prepared by outgrowth of skin biopsies and cultured as described (69) (70) (71) . 
RNAi and overexpression experiments
Dermal fibroblasts were transfected with 3 µg of small interfering RNA duplexes against SOCS3, JAK2, DNMT1, DNMT3A, SMAD3 or SMAD4 using the 4D-Nucleofector Kit for human dermal fibroblasts (Lonza Cologne GmbH, Cologne, Germany) as previously described (70, 72) . The sequences of the siRNAs are summarized in supplementary table 1. Fibroblasts transfected with non-targeting siRNAs (Eurogentec, Seraing, Belgium) served as controls.
In order to overexpress SOCS3 in dermal fibroblasts, the cDNA of SOCS3 was cloned into pcDNA3.1(+) expression vectors (Thermo Fisher Scientific, Waltham, MA, USA).
The plasmid pGEM-JAK2 encoding the human JAK2 gene was purchased from Sino Biological (Beijing, China). In vitro mutagenesis of the GQM-binding motif for SOCS3 of JAK2 was performed using the QuickChange Multi site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA) to obtain the mutant JAK2-G1071V;M1073A which cannot be inhibited by SOCS3 (36) . After verification of the correct sequence, the constructs were transfected in dermal human fibroblasts using the Lonza 4D-Nucleofector kit. Fibroblasts were transfected with five µg of plasmids (73) . Transfections with the empty or non-mutated wildtype vectors were used as controls.
Methylation-specific PCR and Methylated DNA immunoprecipitation (MeDIP)
Genomic DNA was isolated from fibroblasts of SSc patients and healthy volunteers using the Qiagen DNeasy extraction system (Qiagen, Hilden, Germany) according to the instructions of the manufacturer. 
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed using the ChIP-IT Express kit (Active Motif) as described (74) . 
Reporter assay
Fibroblasts were transfected with one µg of STAT3-luciferase reporter construct (Qiagen) in serum-free medium using the Lonza 4D-Nucleofector kit (73) . Transfected cells were incubated with TGFβ and 5-aza for 16 h and harvested 36 h after transfection. A non-inducible luciferase vector was used as control. Luciferase activity was determined using a microplate luminometer (Berthold Technologies, Bad Herrenalb, Germany).
Quantitative real-time PCR
Total RNA was isolated with the NucleoSpin RNA II extraction system (Macherey-Nagel, Düren, Germany) and reverse transcribed into cDNA as described (75, 76) . Gene expression was quantified by real-time PCR using the Mx3005P Sequence Detection System (Agilent Technologies). Specific primer pairs for each gene were designed with the Primer 3 software.
The primer sequences used are given in supplementary table 3. Measurement of β-actin levels was used to normalize for the amounts of loaded cDNA. Samples without enzyme in the reverse transcription reaction, without template and dissociation curve analysis served as controls.
Differences were calculated with the threshold cycle (Ct) and the comparative Ct method for relative quantification. 
Western Blot
Co-Immunoprecipitation (CoIP)
Fibroblasts were collected in lysis buffer (20 mM TRIS-HCl pH 8, 137 mM NaCl, 10 % Glycerol, 1 % NP-40, and 2 mM EDTA). Cell extracts were incubated with rabbit anti-JAK2
(clone D2E12, #3230, Cell Signaling Technology) or normal rabbit IgG antibodies (Vector Laboratories, Burlingame, CA, USA) and 20 μl of protein A/G Agarose (Santa Cruz Biotechnology). Unbound proteins were removed by washing with PBS. Agarose-bound protein complexes were separated via SDS-PAGE followed by western blotting on a PVDF membrane. Ten percent of the lysates was used as input.
Collagen measurements
Total soluble collagen in cell culture supernatants was quantified using the SirCol collagen assay (Biocolor, Belfast, Northern Ireland) as described (75) . The absorbance was determined at 540 nm with a Spectra MAX 190 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Murine models of fibrosis
Bleomycin-induced fibrosis was induced by subcutaneous injections of bleomycin every other day as described (77, 78) . In order to analyze the efficiency of 5-aza for treatment of established fibrosis, the mouse model of pre-established bleomycin-induced dermal fibrosis was used in 6-
week-old female DBA/2 mice (Janvier Labs, Le Genest-Saint-Isle, France) (79). One group receiving bleomycin for six weeks was additionally treated with intraperitoneal injections of 5aza for the last three weeks at a dose of 0.5 mg/kg every third day.
In addition to the model of bleomycin-induced dermal fibrosis, we also used the model of dermal fibrosis induced by local overexpression of constitutively active TGFβ receptor type I (TBRI act ) as previously described (72, 77) . Briefly, mice were injected with 6.67 x 10 7 ifu of TBRI act -AAV5 every other week. Control mice were injected with the same amounts of LacZencoding AAV5. Mice were sacrificed after eight weeks for further analyses. 
Conditional knockout of Socs3 and Dnmt3a
Mice with conditional alleles of Socs3 (Socs3 fl/fl ) (83) 
siRNA-mediated knockdown of Dnmt1 and Dnmt3a in murine skin
Female DBA/2 mice at an age of six weeks were purchased from Janvier Labs (Janvier Labs, Le Genest-Saint-Isle, France). Complexes of siRNA and atelocollagen (Koken, Tokyo, Japan)
were prepared as described previously (86, 87 Tukey's range test as post hoc analysis was used. A p-value less than 0.05 was considered significant. Significance levels are expressed as follows: 0.05 > p ≥ 0.01 as *; 0.01 > p ≥ 0.001 as **; p < 0.001 as ***.
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